Results from the TRACT trial, published today in the New England Journal of Medicine and funded by the Medical Research Council (MRC), show that children with complicated severe anaemia who do not have a fever require larger volumes of blood transfusions than current World Health Organisation (WHO) guidelines.
These results will help doctors and guideline developers make sure children with severe anaemia receive safe and effective treatment
Professor Kath Maitland Study author
However, for children admitted to hospital with a high temperature (fever), the amount recommended by guidelines is correct. Children who received the appropriate amount of blood, depending on whether they had fever or not, were at about half the risk of dying compared to those who received the other amount.
The TRACT trial also showed that children with uncomplicated severe anaemia do not require an immediate transfusion, as long as they are closely monitored for signs of complications, or their haemoglobin levels dropping, and receive a transfusion at that point.
Severe anaemia is common and life-threatening for children in sub-Saharan Africa. Around one in ten children in hospital with severe anaemia die while in hospital, and one in eight die within six months of being discharged from hospital. One in six children end up back in hospital within six months of being discharged.
Professor Sarah Walker (MRC Clinical Trials Unit at UCL) said: “Blood transfusions are an important treatment for severe anaemia. However, there is little scientific evidence to guide doctors on how much blood to give children, or which children require it. This means international guidelines are based on expert opinion.
“In sub-Saharan Africa there is often not enough blood donated to meet demand for it. Because of this, and the potential risk of side effects from blood transfusions (reactions or infections), the WHO recommend conservative transfusion strategies. But some doctors are concerned that these guidelines do not recommend enough blood.”
The TRACT trial tested two transfusion strategies that aimed to reduce deaths and illness among children with severe anaemia. Among children with severe anaemia whom current guidelines do not recommend giving transfusions to, children were randomly allocated to receive:
- No immediate transfusion (but close monitoring for clinical signs or falling haemoglobin levels showing the child does then need a transfusion)
- Immediate transfusion.
Children who current guidelines say should receive a blood transfusion were randomly allocated to two groups:
- One group received the amount of blood recommended by the guidelines (20mls/kg)
- One group received a larger transfusion (30mls/kg), which is the amount experts think may be needed to correct haemoglobin deficit.
TRACT found no evidence of difference in deaths between children allocated to receive an immediate transfusion versus those who had no immediate transfusion. This supports current guidelines, as long as children are monitored. Around half of children who had no immediate transfusion went on to require a transfusion, mostly because their haemoglobin level fell.
Better chance of survival
Overall, TRACT found no different between children who had larger volume transfusions versus standard transfusions. However, there was strong evidence that the effect of transfusion volume varied by whether the child had a fever at the time of screening (study enrolment), which was at hospital admission in most cases.
- Children without a feverat the time of screening (two thirds of those included in the trial) had half the risk of dying by day 28 if they received 30mls/kg rather than standard 20mls/kg (3% vs 6% absolute risk)
- Children with a fever (>37.5C) at the time of screening had almost half the risk of dying by day 28 if they received 20mls/kg rather than 30mls/kg (3% vs 5% absolute risk)
This suggests guidelines need to be updated to recommend different amounts of blood depending on whether a child has a fever. The trial also showed that very few children developed a transfusion reaction or a side effect such as heart failure or lung oedema, indicating that too much volume had been given.
Chief Investigator, Professor Kath Maitland, Imperial College London said: “Children in TRACT could receive blood in the form of whole blood or concentrated blood (packed cells), which takes time and money to prepare. In TRACT there was no difference in how children did with these two forms of blood. This could save time and resources for blood transfusions services if making packed cells is not necessary.
These results will help doctors and guideline developers make sure children with severe anaemia receive safe and effective treatment.”